Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Clear Secure Inc (YOU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Clear Secure Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.76 (market cap $4.49B), while Clear Secure Inc trades at $54.81 (market cap $5.63B). The key difference: Clear Secure Inc is the larger of the two by market cap, and Clear Secure Inc pays a 1.07% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | YOU | |
|---|---|---|
Market Cap | $4.49B | $5.63B |
Sector | Health | Technology |
52-Week High | $28.06 | $62.36 |
52-Week Low | $20.06 | $28.38 |
Enterprise Value | $3.69B | $4.94B |
Dividend Yield | — | 1.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Clear Secure (YOU) trades at $56.74, up 5.48% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with 65.48% gross margins and 81.15% ROE, though valuation multiples appear elevated at P/E 45.39. Recent Q1 2026 earnings beat expectations, and the AWS partnership expansion signals growth potential. Analyst sentiment is mixed with 44% buy ratings and consensus target near current price.
Outlook remains positive given strong member growth and cash flow generation, but high valuation multiples and competitive pressures present risks. The stock's technical overbought condition near resistance at $58 suggests potential near-term consolidation before further upside. Institutional interest appears balanced with moderate net cash flow growth supporting expansion initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Clear Secure Inc
Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →
